Akihiko Umeno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Akihiko Umeno has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Eisuke Ueshima
Department of Radiology, Kobe University Graduate School of Medicine
2 shared publications - Keitaro Sofue
Department of Radiology Kobe University Graduate School of Medicine Kobe Japan
2 shared publications - Kentaro Nishiuchi
Department of Radiology, Kobe University Graduate School of Medicine
2 shared publications - Takamichi Murakami
Department of Radiology, Kobe University Graduate School of Medicine
2 shared publications - Takeru Yamaguchi
Department of Radiology, Kobe University Graduate School of Medicine, 7-5-2, Kusunokicho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan
2 shared publications - Atsuhiro Masuda
Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
1 shared publication
Latest Publications
- 23 September 2026
- Published by Wolters Kluwer Health in Journal of Computer Assisted Tomography
Super-Resolution Deep Learning Reconstruction for 3-Dimensional T1-Weighted Gradient-Echo Imaging in Contrast-Enhanced Liver MRI: Comparison With Conventional and Standard Deep Learning Reconstructions
Purpose: To evaluate the image quality of super-resolution deep learning reconstruction (SR-DLR) for 3-dimensional (3D) T1-weighted gradient-echo (GRE) imaging in contrast-enhanced MRI, compared with conventional reconstruction (Conv.) and standard deep learning reconstruction (DLR). Materials and Methods: This retrospective study included 50 patients (mean age: 71.5 y) with 76 hepatic lesions who underwent contrast-enhanced dynamic liver MRI at 3T. Portal venous phase images were reconstructed using Conv., DLR, and SR-DLR. Quantitative analyses measured liver signal-to-noise ratio (SNR), contrast ratio (CR) between liver parenchyma and lesions, edge rise distance (ERD), and edge rise slope (ERS). Qualitative assessments of image noise, sharpness, contrast, motion artifacts, overall image quality, and lesion conspicuity were performed independently by 2 radiologists using a 5-point scale. Coronal multiplanar reformatted (MPR) images were also evaluated. Statistical comparisons were performed using the Friedman test with Bonferroni correction. Results: Liver SNR was comparable between SR-DLR and DLR. SR-DLR produced sharper edges (lower ERD, higher ERS) and higher lesion-to-liver CR than Conv. and DLR ( P P <0.001). SR-DLR images exhibited slightly higher image noise and motion-related artifacts than DLR. Conclusion: SR-DLR improved spatial resolution, sharpness, and lesion conspicuity in contrast-enhanced MRI compared with Conv. and DLR, indicating potential to improve the diagnostic performance of dynamic liver MRI.
- 23 September 2026
- Published by Wolters Kluwer Health in Journal of Computer Assisted Tomography
Super-Resolution Deep Learning Reconstruction for 3-Dimensional T1-Weighted Gradient-Echo Imaging in Contrast-Enhanced Liver MRI: Comparison With Conventional and Standard Deep Learning Reconstructions
Purpose: To evaluate the image quality of super-resolution deep learning reconstruction (SR-DLR) for 3-dimensional (3D) T1-weighted gradient-echo (GRE) imaging in contrast-enhanced MRI, compared with conventional reconstruction (Conv.) and standard deep learning reconstruction (DLR). Materials and Methods: This retrospective study included 50 patients (mean age: 71.5 y) with 76 hepatic lesions who underwent contrast-enhanced dynamic liver MRI at 3T. Portal venous phase images were reconstructed using Conv., DLR, and SR-DLR. Quantitative analyses measured liver signal-to-noise ratio (SNR), contrast ratio (CR) between liver parenchyma and lesions, edge rise distance (ERD), and edge rise slope (ERS). Qualitative assessments of image noise, sharpness, contrast, motion artifacts, overall image quality, and lesion conspicuity were performed independently by 2 radiologists using a 5-point scale. Coronal multiplanar reformatted (MPR) images were also evaluated. Statistical comparisons were performed using the Friedman test with Bonferroni correction. Results: Liver SNR was comparable between SR-DLR and DLR. SR-DLR produced sharper edges (lower ERD, higher ERS) and higher lesion-to-liver CR than Conv. and DLR ( P P <0.001). SR-DLR images exhibited slightly higher image noise and motion-related artifacts than DLR. Conclusion: SR-DLR improved spatial resolution, sharpness, and lesion conspicuity in contrast-enhanced MRI compared with Conv. and DLR, indicating potential to improve the diagnostic performance of dynamic liver MRI.
- Open Access
Immunoscore Predicted by Dynamic Contrast-Enhanced Computed Tomography Can Be a Non-Invasive Biomarker for Immunotherapy Susceptibility of Hepatocellular Carcinoma
Background/Objectives: Although immunotherapy is the primary treatment option for intermediate-stage hepatocellular carcinoma (HCC), its efficacy varies. This study aimed to identify non-invasive imaging biomarkers predictive of the immunoscore linked to dynamic contrast-enhanced computed tomography (CECT). Methods: We performed immunohistochemical staining with CD3+ and CD8+ antibodies and counted the positive cells in the invasive margin (IM) and central tumor (CT), converting them to an immunoscore of 0 to 4 points. We assessed the dynamic CECT findings obtained from 96 patients who underwent hepatectomy for HCC and evaluated the relationship between dynamic CECT findings and immunoscores. For validation, we assessed the treatment effects on 81 nodules using the Response Evaluation Criteria in Solid Tumors in another cohort of 41 patients who received combined immunotherapy with atezolizumab and bevacizumab (n = 27) and durvalumab and tremelizumab (n = 14). Results: HCCs with peritumoral enhancement in the arterial phase (p < 0.001) and rim APHE (p = 0.009) were associated with the immunoscore in univariate linear regression analysis and peritumoral enhancement in the arterial phase (p = 0.004) in multivariate linear regression analysis. The time to nodular progression in HCCs with peritumoral enhancement in the arterial phase was significantly longer than that in HCCs without this feature (p < 0.001). Conclusions: We identified HCCs with peritumoral enhancement in the arterial phase as a noninvasive imaging biomarker to predict immune-inflamed HCC with a high immunoscore tendency. These HCCs were most likely to respond to combined immunotherapy.
Open AccessImmunoscore Predicted by Dynamic Contrast-Enhanced Computed Tomography Can Be a Non-Invasive Biomarker for Immunotherapy Susceptibility of Hepatocellular Carcinoma
Background/Objectives: Although immunotherapy is the primary treatment option for intermediate-stage hepatocellular carcinoma (HCC), its efficacy varies. This study aimed to identify non-invasive imaging biomarkers predictive of the immunoscore linked to dynamic contrast-enhanced computed tomography (CECT). Methods: We performed immunohistochemical staining with CD3+ and CD8+ antibodies and counted the positive cells in the invasive margin (IM) and central tumor (CT), converting them to an immunoscore of 0 to 4 points. We assessed the dynamic CECT findings obtained from 96 patients who underwent hepatectomy for HCC and evaluated the relationship between dynamic CECT findings and immunoscores. For validation, we assessed the treatment effects on 81 nodules using the Response Evaluation Criteria in Solid Tumors in another cohort of 41 patients who received combined immunotherapy with atezolizumab and bevacizumab (n = 27) and durvalumab and tremelizumab (n = 14). Results: HCCs with peritumoral enhancement in the arterial phase (p < 0.001) and rim APHE (p = 0.009) were associated with the immunoscore in univariate linear regression analysis and peritumoral enhancement in the arterial phase (p = 0.004) in multivariate linear regression analysis. The time to nodular progression in HCCs with peritumoral enhancement in the arterial phase was significantly longer than that in HCCs without this feature (p < 0.001). Conclusions: We identified HCCs with peritumoral enhancement in the arterial phase as a noninvasive imaging biomarker to predict immune-inflamed HCC with a high immunoscore tendency. These HCCs were most likely to respond to combined immunotherapy.